^
Association details:
Biomarker:No biomarker
Cancer:Neuroendocrine Tumor
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Poorly Differentiated Neuroendocrine Carcinoma/Large or Small Cell (Extrapulmonary): Locoregional Unresectable/Metastatic Disease:...Pembrolizumab.